WithdrawnPHASE1, PHASE2NCT03873025
A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Studying Epstein-Barr virus-positive diffuse large B-cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University College, London
- Principal Investigator
- Graham CollinsOxford University Hospitals NHS Trust
- Intervention
- Pembrolizumab and CXD101(combination_product)
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2025
Collaborators
Celleron Therapeutics Ltd. · Merck Sharp & Dohme LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03873025 on ClinicalTrials.govOther trials for Epstein-Barr virus-positive diffuse large B-cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGEARLY PHASE1NCT07162012Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive LymphomaShanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- RECRUITINGPHASE2NCT06846463Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+Virginia Commonwealth University
- RECRUITINGNCT06588205Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell LymphomaFondazione Italiana Linfomi - ETS
- RECRUITINGPHASE3NCT06929624A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell LymphomaSuzhou Suncadia Biopharmaceuticals Co., Ltd.
- RECRUITINGNCT06830759Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular LymphomaAbbVie
- RECRUITINGPHASE1NCT06830031Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell LymphomaShanghai Exuma Biotechnology Ltd.
- RECRUITINGNCT07198230Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell LymphomaTing YANG
- RECRUITINGPHASE2NCT07254754Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell LymphomaGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea
See all trials for Epstein-Barr virus-positive diffuse large B-cell lymphoma →